BioSig Subsidiary ViralClear Submits Application for Vicromax Through FDA's Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials

Press/Media: Expert Comment

PeriodApr 21 2020

Media coverage

1

Media coverage

  • TitleBioSig Subsidiary ViralClear Submits Application for Vicromax Through FDA's Coronavirus Treatment Acceleration Program (CTAP) to Seek Acceleration of its Planned Clinical Trials
    Media name/outletIndia Pharma News
    CountryIndia
    Date4/21/20
    PersonsSlobodan Paessler, Cheng Huang

Keywords

  • COVID-19